Mesoridazine Besylate

苯磺酸美索达嗪

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameMesoridazine Besylate
Drug Alias Namemesoridazinum美索哒嗪mesoridazina苯磺酸甲砜达嗪美索达嗪苯磺酸盐 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1970/02/27
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN05AC03
Related LinksWikipediaDrugBankKEGG